Physician profile
Andy E Shen
NPI 1578734349
$7,192.01
in general payments reported to CMS, 2019-2025
43 companies · $715 in 2025
The $715 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,049 · 2020: $820 · 2021: $836 · 2022: $870 · 2023: $1,537 · 2024: $1,364 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,616.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,549.62 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Astrazeneca Pharmaceuticals LP | $901.37 | 2019-2024 | Airsupra, Farxiga |
| Novo Nordisk INC | $648.67 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $530.84 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $451.75 | 2019-2025 | Repatha, Evenity, Otezla |
| Amarin Pharma, INC. | $352.65 | 2019-2023 | |
| Pfizer INC. | $280.03 | 2019-2024 | |
| Glaxosmithkline, LLC. | $274.12 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.45 | 2019-2024 | Jardiance, Synjardy, Trijardy Xr |
| Astellas Pharma US INC | $190.13 | 2019-2022 | |
| Corcept Therapeutics | $146.27 | 2024-2025 | Korlym |
| Horizon Therapeutics Plc | $134.76 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.36 | 2020-2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $128.03 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $124.99 | 2024 | Voquezna |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andy Shen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.